These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
4. Tumor treating fields plus temozolomide for newly diagnosed glioblastoma: a sub-group analysis of Korean patients in the EF-14 phase 3 trial. Kim CY; Paek SH; Nam DH; Chang JH; Hong YK; Kim JH; Kim OL; Kim SH J Neurooncol; 2020 Feb; 146(3):399-406. PubMed ID: 32020470 [TBL] [Abstract][Full Text] [Related]
5. Health-related quality of life, cognitive screening, and functional status in a randomized phase III trial (EF-14) of tumor treating fields with temozolomide compared to temozolomide alone in newly diagnosed glioblastoma. Zhu JJ; Demireva P; Kanner AA; Pannullo S; Mehdorn M; Avgeropoulos N; Salmaggi A; Silvani A; Goldlust S; David C; Benouaich-Amiel A; J Neurooncol; 2017 Dec; 135(3):545-552. PubMed ID: 28849310 [TBL] [Abstract][Full Text] [Related]
6. Maintenance Therapy With Tumor-Treating Fields Plus Temozolomide vs Temozolomide Alone for Glioblastoma: A Randomized Clinical Trial. Stupp R; Taillibert S; Kanner AA; Kesari S; Steinberg DM; Toms SA; Taylor LP; Lieberman F; Silvani A; Fink KL; Barnett GH; Zhu JJ; Henson JW; Engelhard HH; Chen TC; Tran DD; Sroubek J; Tran ND; Hottinger AF; Landolfi J; Desai R; Caroli M; Kew Y; Honnorat J; Idbaih A; Kirson ED; Weinberg U; Palti Y; Hegi ME; Ram Z JAMA; 2015 Dec; 314(23):2535-43. PubMed ID: 26670971 [TBL] [Abstract][Full Text] [Related]
7. What is the Role of Tumor-treating Fields in Newly Diagnosed Glioblastoma? Ornelas AS; Porter AB; Sharma A; Knox MG; Marks LA; Wingerchuk DM; O'Carroll CB Neurologist; 2019 Mar; 24(2):71-73. PubMed ID: 30817495 [TBL] [Abstract][Full Text] [Related]
8. Increased compliance with tumor treating fields therapy is prognostic for improved survival in the treatment of glioblastoma: a subgroup analysis of the EF-14 phase III trial. Toms SA; Kim CY; Nicholas G; Ram Z J Neurooncol; 2019 Jan; 141(2):467-473. PubMed ID: 30506499 [TBL] [Abstract][Full Text] [Related]
9. Effect of Tumor-Treating Fields Plus Maintenance Temozolomide vs Maintenance Temozolomide Alone on Survival in Patients With Glioblastoma: A Randomized Clinical Trial. Stupp R; Taillibert S; Kanner A; Read W; Steinberg D; Lhermitte B; Toms S; Idbaih A; Ahluwalia MS; Fink K; Di Meco F; Lieberman F; Zhu JJ; Stragliotto G; Tran D; Brem S; Hottinger A; Kirson ED; Lavy-Shahaf G; Weinberg U; Kim CY; Paek SH; Nicholas G; Bruna J; Hirte H; Weller M; Palti Y; Hegi ME; Ram Z JAMA; 2017 Dec; 318(23):2306-2316. PubMed ID: 29260225 [TBL] [Abstract][Full Text] [Related]
10. Tumor-treating fields plus chemotherapy versus chemotherapy alone for glioblastoma at first recurrence: a post hoc analysis of the EF-14 trial. Kesari S; Ram Z; CNS Oncol; 2017 Jul; 6(3):185-193. PubMed ID: 28399638 [TBL] [Abstract][Full Text] [Related]
11. Influence of Treatment With Tumor-Treating Fields on Health-Related Quality of Life of Patients With Newly Diagnosed Glioblastoma: A Secondary Analysis of a Randomized Clinical Trial. Taphoorn MJB; Dirven L; Kanner AA; Lavy-Shahaf G; Weinberg U; Taillibert S; Toms SA; Honnorat J; Chen TC; Sroubek J; David C; Idbaih A; Easaw JC; Kim CY; Bruna J; Hottinger AF; Kew Y; Roth P; Desai R; Villano JL; Kirson ED; Ram Z; Stupp R JAMA Oncol; 2018 Apr; 4(4):495-504. PubMed ID: 29392280 [TBL] [Abstract][Full Text] [Related]
12. Concurrent chemoradiation and Tumor Treating Fields (TTFields, 200 kHz) for patients with newly diagnosed glioblastoma: patterns of progression in a single institution pilot study. Ali AS; Lombardo J; Niazi MZ; Miller RC; Alnahhas I; Martinez NL; Andrews DW; Judy KD; Shi W J Neurooncol; 2022 Nov; 160(2):345-350. PubMed ID: 36355259 [TBL] [Abstract][Full Text] [Related]
13. Initial experience with scalp sparing radiation with concurrent temozolomide and tumor treatment fields (SPARE) for patients with newly diagnosed glioblastoma. Song A; Bar-Ad V; Martinez N; Glass J; Andrews DW; Judy K; Evans JJ; Farrell CJ; Werner-Wasik M; Chervoneva I; Ly M; Palmer JD; Liu H; Shi W J Neurooncol; 2020 May; 147(3):653-661. PubMed ID: 32206976 [TBL] [Abstract][Full Text] [Related]
14. Long-term therapy with temozolomide is a feasible option for newly diagnosed glioblastoma: a single-institution experience with as many as 101 temozolomide cycles. Barbagallo GM; Paratore S; Caltabiano R; Palmucci S; Parra HS; Privitera G; Motta F; Lanzafame S; Scaglione G; Longo A; Albanese V; Certo F Neurosurg Focus; 2014 Dec; 37(6):E4. PubMed ID: 25434389 [TBL] [Abstract][Full Text] [Related]
15. Tumour Treating Fields (TTFields) in combination with lomustine and temozolomide in patients with newly diagnosed glioblastoma. Lazaridis L; Schäfer N; Teuber-Hanselmann S; Blau T; Schmidt T; Oster C; Weller J; Tzaridis T; Pierscianek D; Keyvani K; Kleinschnitz C; Stuschke M; Scheffler B; Deuschl C; Sure U; Herrlinger U; Kebir S; Glas M J Cancer Res Clin Oncol; 2020 Mar; 146(3):787-792. PubMed ID: 31828428 [TBL] [Abstract][Full Text] [Related]
16. Cost-effectiveness of the long-term use of temozolomide for treating newly diagnosed glioblastoma in Germany. Waschke A; Arefian H; Walter J; Hartmann M; Maschmann J; Kalff R J Neurooncol; 2018 Jun; 138(2):359-367. PubMed ID: 29468446 [TBL] [Abstract][Full Text] [Related]
17. Critical review of the addition of tumor treating fields (TTFields) to the existing standard of care for newly diagnosed glioblastoma patients. Mehta M; Wen P; Nishikawa R; Reardon D; Peters K Crit Rev Oncol Hematol; 2017 Mar; 111():60-65. PubMed ID: 28259296 [TBL] [Abstract][Full Text] [Related]